Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action

• Váldodahkkit: Paola Patrignani (Dahkki), Stefania Tacconelli (Dahkki), Annalisa Contursi (Dahkki), Elena Piazuelo (Dahkki), Annalisa Bruno (Dahkki), Stefania Nobili (Dahkki), Matteo Mazzei (Dahkki), Cristina Milillo (Dahkki), Ulrika Hofling (Dahkki), Gonzalo Hijos-Mallada (Dahkki), Carlos Sostres (Dahkki), Angel Lanas (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Low-dose aspirin's mechanism of action for preventing colorectal cancer (CRC) is still debated, and the optimal dose remains uncertain. We aimed to optimize the aspirin dose for cancer prevention in CRC patients through deep phenotyping using innovative biomarkers for aspirin's...